Evidence map›Paper›PMID 37545861›Full record

ArticleDementia and neurocognitive disorders2023

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer's Disease:

Hyuk Sung Kwon, Seong-Ho Koh, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dementia and neurocognitive disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hyuk Sung KwonDepartment of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.ORCID https://orcid.org/0000-0002-2005-0983
Seong-Ho KohDepartment of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.ORCID https://orcid.org/0000-0001-5419-5761
Seong Hye ChoiDepartment of Neurology, Inha University School of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0002-4180-8626
Jee Hyang JeongDepartment of Neurology, Ewha Womans University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7945-6956
Hae Ri NaDepartment of Neurology, Bobath Memorial Hospital, Seongnam, Korea.ORCID https://orcid.org/0000-0002-3419-8428
Chan Nyoung LeeDepartment of Neurology, Korea University Anam Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-1285-4658
YoungSoon YangDepartment of Neurology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.ORCID https://orcid.org/0000-0002-2448-2599
Ae Young LeeDepartment of Neurology, Chungnam National University Hospital, Daejeon, Korea.ORCID https://orcid.org/0000-0001-9790-0838
Jae-Hong LeeDepartment of Neurology, Asan Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0001-7368-4560
Kyung Won ParkDepartment of Neurology, Dong-A University Hospital, Busan, Korea.ORCID https://orcid.org/0000-0002-6788-5267
Hyun Jeong HanDepartment of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.ORCID https://orcid.org/0000-0002-1129-6340
Byeong C KimDepartment of Neurology, Chonnam National University Medical School and Hospital, Gwangju, Korea.ORCID https://orcid.org/0000-0001-6827-6730
Jinse ParkDepartment of Neurology, Haeundae Paik Hospital, Inje University, Buasn, Korea.ORCID https://orcid.org/0000-0001-8738-5422
Jee-Young LeeDepartment of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-9120-2075
Kyu-Yong LeeDepartment of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.ORCID https://orcid.org/0000-0001-8855-7513
Sangjae KimTeloid Inc., Los Angeles, CA, USA.ORCID https://orcid.org/0009-0003-8877-1060

Funding

NIEHS NIH HHS 27398C0007
6 · The paper itself

Abstract

Background and Purpose: The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer's disease (AD). In this study, we aimed to further demonstrate the effectiveness of GV1001 using subscales of the Severe Impairment Battery (SIB), which is a validated measure to assess cognitive function in patients with moderate-to-severe AD. Methods: We performed a Results: In addition to the considerable beneficial effect of GV1001 on the SIB total score, GV1001 1.12 mg showed the most significant effect on language function at 24 weeks compared to placebo in both the full analysis set (FAS) and per-protocol set (PPS) ( Conclusions: Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.

Indexed as

Alzheimer’s DiseaseEfficacyGV1001Language

Identifiers

PMID37545861
PMCPMC10400345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.